Top 10 Daridorexant (Quviviq) Generic Manufacturers in Israel
The pharmaceutical industry in Israel is experiencing significant growth, driven by a robust ecosystem of innovation and an increasing demand for generic medications. According to recent data, the Israeli pharmaceuticals market was valued at approximately $4.5 billion in 2022, with exports accounting for around 75% of this figure. As generics continue to gain traction due to their cost-effectiveness, several manufacturers are emerging as key players in the production of Daridorexant (Quviviq) generics, which are gaining attention in both domestic and international markets.
1. Teva Pharmaceutical Industries Ltd.
Teva is Israel’s largest pharmaceutical company, holding a significant share of the global generics market. In 2022, Teva reported revenues of approximately $16.3 billion, with generics contributing around 60%. The company is actively involved in developing Daridorexant generics, leveraging its extensive R&D capabilities.
2. Mylan N.V. (now part of Viatris)
Mylan, which merged with Upjohn (a division of Pfizer) to form Viatris, has a strong presence in Israel. The company reported generics sales of approximately $11.3 billion globally in 2022. Their investments in local manufacturing help ensure a steady supply of Daridorexant alternatives.
3. Perrigo Company plc
Perrigo is a notable player in the Israeli generics market, focusing on over-the-counter and prescription medications. With a revenue of approximately $4.9 billion in 2022, the company is expanding its portfolio to include Daridorexant generics, responding to increasing market demand.
4. Kamada Ltd.
Kamada specializes in biopharmaceuticals and is expanding its generic offerings. In 2022, the company’s revenue was around $100 million, with growing contributions from generic products. Their focus on Daridorexant reflects their strategy to diversify their product range.
5. Clalit Health Services
As one of Israel’s largest health maintenance organizations, Clalit has ventured into pharmaceutical manufacturing. With a production capacity that supplies a significant portion of the generic market, Clalit is poised to introduce Daridorexant generics, enhancing access for their members.
6. Taro Pharmaceutical Industries Ltd.
Taro is known for its dermatological and generic products. The company reported revenue of approximately $200 million in 2022, focusing on expanding its generic portfolio, which now includes plans for Daridorexant alternatives.
7. Bio-Technology General (BTG)
BTG is a subsidiary of Teva and has been involved in developing generic biologics. The company has a production capacity aligning with its parent company, enabling it to explore the generic production of Daridorexant effectively.
8. Neopharm Group
Neopharm Group is a leading Israeli pharmaceutical distributor and developer, with revenues surpassing $400 million in 2022. Their focus on generic formulations, including Daridorexant, addresses the growing need for affordable medication solutions.
9. Dexcel Pharma Technologies Ltd.
Dexcel is focused on the development and marketing of generics and specialty pharmaceuticals. With a revenue of approximately $160 million in 2022, the company is adding Daridorexant to its diverse product offerings, which enhances its market presence.
10. Medison Pharma
Medison specializes in the commercialization of pharmaceuticals in Israel. The company reported a revenue of around $150 million in 2022 and is moving towards offering generic versions of high-demand medications, including Daridorexant.
Insights and Trends
The demand for generic medications, particularly in the realm of sleep disorders like those treated by Daridorexant, is projected to rise significantly. The global market for sleep aids is expected to surpass $120 billion by 2026, indicating a potential growth trajectory for generic manufacturers. Israel’s strategic position as a hub for pharmaceutical innovation, combined with its advanced manufacturing capabilities, places it at the forefront of producing generics. As competition increases, companies will likely focus on enhancing their R&D capabilities and expanding their portfolios to capture a larger share of the growing market for sleep medications.
Related Analysis: View Previous Industry Report
